PT - JOURNAL ARTICLE AU - Shinya Tsuzuki AU - Yusuke Miyazato AU - Mari Terada AU - Shinichiro Morioka AU - Norio Ohmagari AU - Philippe Beutels TI - Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients AID - 10.1101/2021.09.27.21264225 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.27.21264225 4099 - http://medrxiv.org/content/early/2021/09/29/2021.09.27.21264225.short 4100 - http://medrxiv.org/content/early/2021/09/29/2021.09.27.21264225.full AB - Background The empirical basis for a quantitative assessment of the disease burden imposed by long-COVID is currently scant. We aimed to assess the disease burden caused by long-COVID in Japan.Methods We conducted a cross sectional self-report questionnaire survey. The questionnaire was mailed to 530 eligible patients, who were recovered from acute COVID-19 in April 2021. Answers were classified into two groups; participants who have no symptom and those who have any ongoing symptoms that lasted longer than four weeks at the time of the survey. We compared health-related quality of life scores estimated by the EQ-5D-3L questionnaire between these two groups after adjusting basic characteristics of the participants by propensity score matching.Results 349 participants reported no symptoms and 108 reported any symptoms at the time of the survey. The participants who reported any symptoms showed a lower value on a Visual Analogue Scale (median 70 [IQR 60-80]) and on the EQ-5D-3L (median 0.81 [IQR 0.77-1.0]) than those reporting no symptoms (median 85 [IQR 75-90] and 1.0 [IQR 1.0-1.0], respectively). After adjusting for background characteristics, these trends did not change substantially (Visual Analog Scale: median 70 [IQR 60-80] vs 80 [IQR 77-90], EQ-5D-3L: median 0.81 [IQR 0.76-1.0] vs 1.0 [IQR 1.0-1.0]).Conclusions Due to their long duration, long-COVID symptoms represent a substantial disease burden expressed in impact on health-related quality of life.Trial registration Not applicable.Competing Interest StatementPB reports grants from the EU's SC1-PHE-CORONAVIRUS-2020 programme, Pfizer, GlaxoSmithKlein, and European Commission IMI, unrelated to this work. Funding StatementThis research was funded by JSPS KAKENHI [Grant number 18K17369], a grant for the National Center for Global Health and Medicine [20A05], AMED under Grant Number JP20fk0108502 and the Health and Labour Sciences Research Grant, Research for risk assessment and implementation of crisis management functions for emerging and re233 emerging infectious diseases.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Ethics Committee of the Center Hospital of the NCGM (NCGM-G-004121-00)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available upon request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.